Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 100,000 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 100,000 shares of the business’s stock in a transaction on Thursday, July 23rd. The stock was sold at an average price of $89.48, for a total value of $8,948,000.00. Following the completion of the transaction, the director directly owned 501,477 shares in the company, valued at approximately $44,872,161.96. This represents a 16.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Liquidia Stock Performance

NASDAQ:LQDA traded down $0.26 during trading on Tuesday, reaching $84.16. The company’s stock had a trading volume of 276,611 shares, compared to its average volume of 1,803,461. Liquidia Corporation has a 12 month low of $16.82 and a 12 month high of $91.10. The firm has a market cap of $7.48 billion, a price-to-earnings ratio of 604.11 and a beta of 0.55. The firm has a 50 day moving average of $71.77 and a 200-day moving average of $50.58. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22.

Liquidia (NASDAQ:LQDA) last released its earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. The company had revenue of $132.87 million for the quarter, compared to analysts’ expectations of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm’s revenue was up 4187.1% compared to the same quarter last year. Research analysts expect that Liquidia Corporation will post 3.02 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Raymond James Financial reiterated a “strong-buy” rating and issued a $68.00 target price on shares of Liquidia in a research note on Thursday, June 4th. Jefferies Financial Group restated a “buy” rating and set a $60.00 price target on shares of Liquidia in a research note on Monday, May 11th. Needham & Company LLC upped their price objective on Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Bank of America reissued a “neutral” rating and set a $79.00 price objective (up from $64.00) on shares of Liquidia in a report on Monday, June 29th. Finally, Wells Fargo & Company raised their target price on Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Liquidia presently has an average rating of “Moderate Buy” and an average price target of $86.18.

Hedge Funds Weigh In On Liquidia

Several large investors have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Liquidia during the 4th quarter valued at approximately $25,000. Covestor Ltd boosted its holdings in shares of Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after acquiring an additional 359 shares during the period. NewEdge Advisors LLC bought a new stake in shares of Liquidia during the 2nd quarter valued at $25,000. Fluent Financial LLC purchased a new stake in Liquidia during the 2nd quarter worth about $287,000. Finally, Fulcrum Equity Management purchased a new stake in Liquidia during the 2nd quarter worth about $399,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).